Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359450 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT00359450 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 186 participants.
The verdict
NCT00359450, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: * Cohort I: Patients previously treated with one taxane containing regimen. * Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen. * Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound. Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.
Interventions
- DRUG BMS-275183 (oral taxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359450
The ClinicalTrials.gov registry entry for NCT00359450 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-275183 (oral taxane) is the first listed.
NCT00359450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359450 about?
NCT00359450 is a clinical study titled "Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)". BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: * Cohort I: Patients previously treated with one taxane containing regimen. * Cohort II: Patients previously ...
What is the current status of trial NCT00359450?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2006-07.
What interventions are being tested in trial NCT00359450?
The interventions under investigation include: BMS-275183 (oral taxane) (DRUG).
Who is sponsoring clinical trial NCT00359450?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.